Magle Chemoswed Holding AB (SE:MAGLE)
:MAGLE
Want to see SE:MAGLE full AI Analyst Report?
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr0.87 - kr27.80
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.06K
Market Cap
kr30.26M
Enterprise Valuekr377.42M
Total Cash (Recent Filing)kr0.00
Total Debt (Recent Filing)kr356.15M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.76
Shares Outstanding30,263,191
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr377.00M
Bulls Say, Bears Say
Bulls Say
Diversified CDMO Services And Manufacturing RevenueMagle's dual model of contract development services plus contract manufacturing creates diversified, fee‑based revenue typical of CDMO firms. This structure generates repeatable project revenue, creates client lock‑in through technical know‑how, and supports resilience across several quarters as projects ramp and renew.
Consistently Very High Gross MarginsSustained very high gross margins indicate strong pricing power and technical differentiation in formulation and production. High gross margins provide structural capacity to absorb SG&A and R&D, improve operating leverage when volumes recover, and support a faster path back to profitability over a multi‑quarter horizon.
Moderate Leverage; Debt Below EquityA moderate capital structure with debt below equity reduces near‑term refinancing pressure and preserves borrowing capacity. This provides financial flexibility to manage working capital or staggered investments during a recovery period, lowering the probability of immediate solvency stress over the next several quarters.
Bears Say
Recent Sharp Revenue Decline And Operating LossesThe reversal from prior growth to TTM revenue contraction and sizable operating losses signals structural demand or execution problems. Persistent operating losses undermine the company's ability to scale fixed‑cost intensive pharma operations, reduce reinvestment capacity, and increase the need for external funding across multiple quarters.
Multi‑period Negative Operating And Free Cash FlowSustained negative operating and free cash flow over several years forces reliance on external financing or dilution. Persistent cash burn limits the company's ability to self‑fund working capital, capital expenditures, or strategic initiatives, raising financing and execution risk over a 2–6 month to multi‑quarter timeframe.
Eroding Equity Base From Recent LossesSignificant equity erosion reduces the financial buffer against shocks and magnifies leverage metrics if losses persist. A dwindling capital base constrains borrowing capacity, increases the probability of covenant breaches or dilution, and narrows strategic options for recovery over the medium term.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr0.86 and its highest was kr27.80 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr30.26M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Aug 05, 2026 which is in 47 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on May 18, 2026. The company reported -kr1.068 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.068.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of N/A. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 30,263,191 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -kr1.068 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.474%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Technical Analysis
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Corline Biomedical AB
―